MC
CRL icon

Moors & Cabot’s Charles River Laboratories CRL Stock Holding History

Moors & Cabot’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4
Closed -$3K – 921
2021
Q4 		$3K Buy
+4
New +$1.55K ﹤0.01% 881

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Moors & Cabot's CRL Position: Q1 2026 in Review

Moors & Cabot increased its Charles River Laboratories (CRL) stake by 0.71% in Q1 2026, buying an estimated $2.23K and bringing the position to 1,697 shares worth $293K. The position accounts for 0.01% of the portfolio, ranked #711.

Moors & Cabot first reported a position in CRL in Q3 2021 and has held it in 19 quarters since. The position peaked at $743K in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Moors & Cabot held 1,697 shares of Charles River Laboratories worth $293K as of Q1 2026.
  • Moors & Cabot bought 12 Charles River Laboratories shares in Q1 2026, an estimated $2.23K.
  • Charles River Laboratories made up 0.01% of Moors & Cabot's portfolio in Q1 2026, its #711 holding.
  • Moors & Cabot first reported a position in Charles River Laboratories in Q3 2021 and has held it in 19 quarters since.
  • Moors & Cabot's Charles River Laboratories position peaked at $743K in Q3 2021.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.